PMID- 29490771
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190128
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 39
IP  - 2
DP  - 2018 Mar 1
TI  - Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and 
      secretion from human laboratory of allergic diseases 2 mast cells stimulated by 
      substance P and/or immunoglobulin E.
PG  - 153-160
LID - 10.2500/aap.2018.38.4105 [doi]
AB  - BACKGROUND: Cytokine interleukin (IL) 31 has emerged as an important component of 
      allergic and inflammatory diseases associated with pruritus, such as atopic 
      dermatitis (AD) and mastocytosis. Mast cells (MC) are stimulated by allergic and 
      nonallergic triggers, and play a critical role in such diseases by secreting 
      histamine and tryptase as well as cytokines and chemokines. IL-33 has been 
      reported to augment MC responses, but its effect on secretion of IL-31 is not 
      known. OBJECTIVES: To investigate whether IL-33 can stimulate the secretion of 
      IL-31 from cultured human MCs and whether this response is augmented by either 
      the neuropeptide substance P (SP) or immunoglobulin E (IgE) and anti-IgE in the 
      absence or presence of IL-4. METHODS: Laboratory of Allergic Diseases (LAD2) 
      human MCs were cultured in StemProH-34 SFM medium supplemented by stem cell 
      factor and were stimulated either with IL-33 (10 ng /mL) or SP (2 muM), or 
      preincubated with IgE (1 mug/mL) overnight, and then stimulated with anti-IgE (1 
      mug/mL) for 24 hours. IL-31 gene expression was measured by quantitative 
      polymerase chain reaction, and protein was measured by enzyme-linked 
      immunosorbent assay. RESULTS: IL-33 (10 ng/mL) induces IL-31 gene expression, 
      synthesis, and secretion from LAD2 cells in the absence of degranulation, whereas 
      SP and IgE on their own have no effect. However, the effect of IL-33 is augmented 
      by SP (2 muM) and/or IgE and anti-IgE (1 mug/mL both) and especially their 
      combination. Moreover, this response is significantly further increased when LAD2 
      cells are cultured in the presence of IL-4. CONCLUSION: These findings provide 
      evidence that IL-33 induced secretion of IL-31 from LAD2 MC, an action augmented 
      by novel neuroimmune interactions that may help in the development of new 
      treatments of allergic and inflammatory diseases, especially AD and mastocytosis.
FAU - Petra, Anastasia I
AU  - Petra AI
AD  - Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of 
      Integrative Physiology and Pathobiology, Tufts University School of Medicine, 
      Boston. Massachusetts, USA.
FAU - Tsilioni, Irene
AU  - Tsilioni I
AD  - Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of 
      Integrative Physiology and Pathobiology, Tufts University School of Medicine, 
      Boston. Massachusetts, USA.
FAU - Taracanova, Alexandra
AU  - Taracanova A
AD  - Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of 
      Integrative Physiology and Pathobiology, Tufts University School of Medicine, 
      Boston. Massachusetts, USA.
FAU - Katsarou-Katsari, Alexandra
AU  - Katsarou-Katsari A
AD  - First Department of Dermatology, A. Syggros Hospital, Athens University Medical 
      School, Athens, Greece.
FAU - Theoharides, Theoharis C
AU  - Theoharides TC
AD  - Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of 
      Integrative Physiology and Pathobiology, Tufts University School of Medicine, 
      Boston. Massachusetts, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (IL31 protein, human)
RN  - 0 (IL33 protein, human)
RN  - 0 (IL4 protein, human)
RN  - 0 (Interleukin-33)
RN  - 0 (Interleukins)
RN  - 207137-56-2 (Interleukin-4)
RN  - 33507-63-0 (Substance P)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Cell Degranulation
MH  - Cell Line
MH  - Gene Expression Regulation
MH  - Humans
MH  - Hypersensitivity/*immunology
MH  - Immunoglobulin E/immunology
MH  - Interleukin-33/*metabolism
MH  - Interleukin-4/*metabolism
MH  - Interleukins/genetics/*metabolism
MH  - Mast Cells/*immunology
MH  - Neuroimmunomodulation
MH  - Substance P/immunology
PMC - PMC5827155
COIS- The authors have no conflicts of interest to declare pertaining to this article
EDAT- 2018/03/02 06:00
MHDA- 2019/01/29 06:00
PMCR- 2018/03/01
CRDT- 2018/03/02 06:00
PHST- 2018/03/02 06:00 [entrez]
PHST- 2018/03/02 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/03/01 00:00 [pmc-release]
AID - AAP137-17 [pii]
AID - 10.2500/aap.2018.38.4105 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2018 Mar 1;39(2):153-160. doi: 10.2500/aap.2018.38.4105.